Retrospective real-world comparison of medical visits,costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia

Abstract

Objective:

To compare healthcare resource utilization, costs, and treatment adherence associated with dasatinib versus nilotinib treatment as second-line therapies in chronic myeloid leukemia (CML) patients.